These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26786928)

  • 21. Infliximab Therapy for Corticosteroid-Resistant Ipilimumab-Induced Colitis.
    Beniwal-Patel P; Matkowskyj K; Caldera F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):274. PubMed ID: 26405697
    [No Abstract]   [Full Text] [Related]  

  • 22. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
    N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A new form of hypophisitis following ipilimumab therapy].
    Schmutz JL
    Ann Dermatol Venereol; 2015 Apr; 142(4):307-8. PubMed ID: 25770731
    [No Abstract]   [Full Text] [Related]  

  • 24. [Immunotherapies and melanoma].
    Routier É; Robert C; Mateus C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S13-24. PubMed ID: 25776763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vemurafenib sensitivity skin reaction after ipilimumab.
    Harding JJ; Pulitzer M; Chapman PB
    N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
    [No Abstract]   [Full Text] [Related]  

  • 26. [Ipilimumab-induced hypophysitis].
    Schleder S; Schreml S; Heiss P
    Rofo; 2013 Mar; 185(3):268-9. PubMed ID: 23154861
    [No Abstract]   [Full Text] [Related]  

  • 27. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nivolumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of immune-related adverse events and kinetics of response with ipilimumab.
    Weber JS; Kähler KC; Hauschild A
    J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
    Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
    Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ipilimumab in patients with cancer and the management of dermatologic adverse events.
    Lacouture ME; Wolchok JD; Yosipovitch G; Kähler KC; Busam KJ; Hauschild A
    J Am Acad Dermatol; 2014 Jul; 71(1):161-9. PubMed ID: 24767731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.
    Pintova S; Sidhu H; Friedlander PA; Holcombe RF
    Melanoma Res; 2013 Dec; 23(6):498-501. PubMed ID: 24113862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 35. Melanoma and a Headache. Diagnosis: Hypophysitis.
    Johnson DB; Mudigonda TV; Sosman JA
    JAMA Oncol; 2015 Nov; 1(8):1167-8. PubMed ID: 26225893
    [No Abstract]   [Full Text] [Related]  

  • 36. Exacerbation of Psoriasis During Nivolumab Therapy for Metastatic Melanoma.
    Matsumura N; Ohtsuka M; Kikuchi N; Yamamoto T
    Acta Derm Venereol; 2016 Feb; 96(2):259-60. PubMed ID: 26270860
    [No Abstract]   [Full Text] [Related]  

  • 37. A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment.
    Humayun MA; Poole R
    Hormones (Athens); 2016 Apr; 15(2):303-306. PubMed ID: 27376434
    [No Abstract]   [Full Text] [Related]  

  • 38. Rare heart risk found with checkpoint inhibitors.
    Printz C
    Cancer; 2017 May; 123(9):1483-1484. PubMed ID: 28430361
    [No Abstract]   [Full Text] [Related]  

  • 39. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic score for patients with advanced melanoma treated with ipilimumab.
    Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
    Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.